Agenus (AGEN)
(Delayed Data from NSDQ)
$15.69 USD
+0.58 (3.84%)
Updated May 31, 2024 04:00 PM ET
After-Market: $15.68 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$15.69 USD
+0.58 (3.84%)
Updated May 31, 2024 04:00 PM ET
After-Market: $15.68 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
Zacks News
Why Is Agenus (AGEN) Down 17.7% Since its Last Earnings Report?
by Zacks Equity Research
Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Agenus (AGEN) Q4 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
Agenus (AGEN) posts wider-than-expected loss and misses on revenue estimate in the fourth quarter of 2017.
Agenus (AGEN) Reports Wider than Expected Q4 Loss, Sales Miss
by Zacks Equity Research
Agenus reports wider than expected loss and misses sales estimates in the fourth quarter of 2017.
What's in Store for Agenus (AGEN) This Earnings Season?
by Zacks Equity Research
Agenus (AGEN) is expected to provide updates on pipeline candidates when it reports Q4 numbers on Mar 8.
Are Options Traders Betting on a Big Move in Agenus (AGEN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Agenus (AGEN) stock based on the movements in the options market lately.
Spectrum Pharmaceuticals Up 134% in 6 Months: Here's Why
by Zacks Equity Research
Spectrum Pharmaceuticals (SPPI) stock is witnessing significant momentum mainly on encouraging data from poziotinib study.
BlackRock, Pier One Imports, Alkermes, Vertex Pharmaceuticals and Agenus highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
BlackRock, Pier One Imports, Alkermes, Vertex Pharmaceuticals and Agenus highlighted as Zacks Bull and Bear of the Day
Agenus Inc., (AGEN) Jumps: Stock Rises 11.4%
by Zacks Equity Research
Agenus Inc. (AGEN) was a big mover last session, as the company saw its shares more than 11% on the day amid huge volumes.
Agenus (AGEN) Reports In Line Loss in Q3, Revenues Lag
by Zacks Equity Research
Agenus (AGEN) incurred in line loss but sales missed estimates in the third quarter of 2017.
Keryx (KERX) Q3 Loss Wider Than Expected, Stock Declines
by Zacks Equity Research
Keryx (KERX) posted wider-than-expected loss in the third quarter of 2017. The company also received approval for label expansion of its lead drug Auryxia.
Prothena (PRTA) Earnings Beat in Q3, Pipeline in Focus
by Zacks Equity Research
Prothena (PRTA) reported a narrower-than-expected loss in the third quarter as the company continued with its pipeline progress.
Agenus (AGEN) Reports In Line Q3 Loss, Sales Miss Estimates
by Zacks Equity Research
Agenus reported in line loss in the third quarter of 2017 but sales missed expectations.
Endocyte (ECYT) Posts Narrower-than-Expected Q3 Loss
by Zacks Equity Research
Endocyte (ECYT) posted narrower-than-expected loss in the third quarter of 2017. The company will focus on the development of PSMA-617 that it licensed in the same quarter.
What's in Store for Ligand (LGND) This Earnings Season?
by Zacks Equity Research
Ligand's (LGND) Captisol formulation technology that helps it form partnerships with several leading healthcare companies might drive the stock in Q3.
What's in Store for Madrigal (MDGL) This Earnings Season?
by Zacks Equity Research
Madrigal (MDGL) expects data readout for its lead candidate MGL-3196 on its third-quarter earnings call.
Inovio (INO) Q3 Earnings: Is a Beat in Store for the Stock?
by Zacks Equity Research
Inovio's (INO) most advanced pipeline candidate, VGX-3100 vaccine's consistent progress might drive the stock in Q3. However, lack of an approved product in the company's portfolio is a dampener.
What's in Store for Catalyst (CPRX) This Earnings Season?
by Zacks Equity Research
Catalyst (CPRX) focus will be on pipeline and regulatory updates at the third-quarter earnings call.
What's in the Cards for Merrimack (MACK) in Q3 Earnings?
by Zacks Equity Research
Merrimack Pharmaceuticals (MACK) will report its third-quarter results later this month. Investors focus is expected to be on pipeline updates.
What's in the Cards for Repros (RPRX) This Earnings Season?
by Zacks Equity Research
Repros Therapeutics (RPRX) will report its third-quarter results later this month. Investors focus is expected to be on pipeline updates.
Spectrum (SPPI) Earnings, Sales Beat Q3 Estimates
by Zacks Equity Research
Spectrum (SPPI) reports narrower-than-expected loss in Q3. Shares up.
Corcept (CORT) Q3 Earnings Miss Estimates, Guidance Raised
by Zacks Equity Research
Corcept Therapeutics' (CORT) earnings miss but sales beat expectations in the third quarter of 2017. The company remains focused on advancing its cortisol modulation platform.
Ironwood (IRWD) Beats Estimates in Q3 Earnings, Stock Up
by Zacks Equity Research
Ironwood Pharmaceuticals (IRWD) beats estimates on both counts in the third quarter. Demand for Linzess rises.
Is a Beat in the Cards for Perrigo (PRGO) in Q3 Earnings?
by Zacks Equity Research
Perrigo's (PRGO) product acquisitions and new product launches in the Rx segment might boost sales in the coming quarters.
AMAG Pharma's (AMAG) Q3 Earnings Beat, Lowers '17 Outlook
by Zacks Equity Research
AMAG Pharmaceuticals' (AMAG) earnings surpassed estimates but missed revenues in the third quarter of 2017.
Horizon Pharma (HZNP) Q3 Earnings: A Disappointment in Store? (revised)
by Zacks Equity Research
Horizon Pharma???s shares have declined 12% in the year so far, underperforming the industry???s gain of 0.9%.